EGFR and triple-negative breast carcinoma: Another experimental therapy undergoing testing by Acepodia is the epidermal growth factor receptor (EGFR)-targeting, ACC Vδ2 T cell therapy for use in combating colorectal, non-small cell lung, and triple-negative breast cancers [218].